Palvella Therapeutics, Inc. SEC filings PVLA

Palvella Therapeutics, Inc. has 816 filings in SEC EDGAR's recent list, going back to Aug 20, 2013. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.

Palvella Therapeutics, Inc. SEC filings
Form Description Filed Period
S-8 Employee stock plan registration Aug 4, 2026 —
424B5 Prospectus supplement Feb 26, 2026 —
424B5 Prospectus supplement Feb 24, 2026 —
S-3 Shelf registration Jan 2, 2026 —
S-8 Employee stock plan registration Feb 18, 2025 —
424B3 Prospectus Jan 17, 2025 —
S-1/A Amended registration statement Jan 14, 2025 —
S-1 Registration statement Dec 31, 2024 —
424B3 Prospectus Nov 8, 2024 —
S-4/A Form s-4/a Nov 7, 2024 —
S-4/A Form s-4/a Nov 5, 2024 —
S-4/A Form s-4/a Oct 29, 2024 —
S-4/A Form s-4/a Oct 15, 2024 —
S-4/A Form s-4/a Sep 23, 2024 —
S-4 Registration for a merger or exchange Aug 9, 2024 —
S-8 Employee stock plan registration Aug 10, 2023 —
424B5 Prospectus supplement Nov 4, 2022 —
S-8 Employee stock plan registration Aug 4, 2022 —
S-8 Employee stock plan registration Aug 5, 2021 —
S-3 Shelf registration Aug 5, 2021 —
424B3 Prospectus Jun 1, 2021 —
S-3 Shelf registration May 17, 2021 —
S-8 Employee stock plan registration Aug 10, 2020 —
S-3 Shelf registration Dec 4, 2019 —
424B5 Prospectus supplement Nov 12, 2019 —
S-8 Employee stock plan registration Nov 12, 2019 —
424B5 Prospectus supplement Aug 9, 2019 —
S-8 Employee stock plan registration Aug 9, 2019 —
S-8 Employee stock plan registration Aug 9, 2018 —
S-8 Employee stock plan registration Aug 9, 2018 —
S-3 Shelf registration Aug 9, 2018 —
424B5 Prospectus supplement Feb 14, 2018 —
424B5 Prospectus supplement Feb 13, 2018 —
S-8 Employee stock plan registration Nov 13, 2017 —
424B5 Prospectus supplement Oct 5, 2016 —
S-8 Employee stock plan registration Sep 23, 2016 —
424B3 Prospectus Aug 4, 2016 —
424B3 Prospectus Aug 4, 2016 —
POS AM Filing Jul 28, 2016 —
S-3/A Filing Jul 28, 2016 —
S-3/A Filing Jul 28, 2016 —
S-3 Shelf registration Jul 8, 2016 —
POS AM Filing Jun 24, 2016 —
424B3 Prospectus Jun 9, 2016 —
424B3 Prospectus Jun 9, 2016 —
424B3 Prospectus Jun 6, 2016 —
S-3 Shelf registration Jun 3, 2016 —
POS AM Filing Apr 14, 2016 —
S-8 Employee stock plan registration Feb 1, 2016 —
424B3 Prospectus Dec 18, 2015 —
424B3 Prospectus Nov 25, 2015 —
424B3 Prospectus Nov 13, 2015 —
424B3 Prospectus Sep 22, 2015 —
424B3 Prospectus Sep 2, 2015 —
424B3 Prospectus Aug 18, 2015 —
424B3 Prospectus Aug 13, 2015 —
424B3 Prospectus Jun 30, 2015 —
424B4 Prospectus Jun 30, 2015 —
S-1/A Amended registration statement Jun 24, 2015 —
S-1/A Amended registration statement Jun 17, 2015 —
S-1 Registration statement Jun 9, 2015 —
S-8 Employee stock plan registration May 27, 2015 —
424B3 Prospectus May 15, 2015 —
424B3 Prospectus May 13, 2015 —
424B3 Prospectus May 12, 2015 —
S-1/A Amended registration statement Apr 20, 2015 —
S-1 Registration statement Feb 17, 2015 —
S-1/A Amended registration statement Jan 13, 2014 —
S-1/A Amended registration statement Dec 11, 2013 —
S-1/A Amended registration statement Nov 21, 2013 —
S-1/A Amended registration statement Sep 30, 2013 —
S-1 Registration statement Aug 20, 2013 —

Showing 72 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
PVLA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Wayne, PA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1583648
Former names
PIERIS PHARMACEUTICALS, INC. (until Dec 12, 2024); Marika Inc. (until Dec 18, 2014)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.